AN2 Therapeutics Inc. (ANTX)
AN2 Therapeutics Inc. (ANTX) Stock Price, Analysis & Data
| Bid | 4.32 |
| Market Cap | 216.23M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -36.28M |
| Beta | -0.99 |
| EPS (ttm) | -1.05 |
| PE Ratio (ttm) | n/a |
| Forward PE | -7.16 |
| P/B (ttm) | 2.52 |
| P/S (ttm) | n/a |
| Earnings Date | Aug 14, 2025 |
| Ask | 7.42 |
| Volume | 266,702 |
| Avg. Volume (20D) | 287,340 |
| Open | 5.96 |
| Previous Close | 5.99 |
| Day's Range | 5.72 - 6.21 |
| 52-Week Range | 1.00 - 7.19 |
| Analyst | Strong Buy |
| Price Target | 9 (57.07%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ANTX
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecul...
Financial Performance
In 2025, AN2 Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -35.17M, a decrease of -31.46%.
Financial StatementsAnalyst Forecast
According to 2 analyst ratings, the average rating for ANTX stock is "Strong Buy". The 12-month stock price forecast is 9, which is upside of 57.07% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
